Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Ainos Inc AIMD

Ainos, Inc. is engaged in developing medical technologies for point-of-care (POCT) testing and medical treatment for a range of disease indications. The Company is engaged in the research and clinical development activities for its programs, securing related intellectual property, and commercializing therapeutics using low-dose non-injectable interferon (IFN). Its Medtech solutions includes COVID-19 Antigen Rapid Test Kit, Volatile Organic Compounds (VOC) POCT-Ainos Flora, VOC POCT-Ainos Pen, VOC POCT-CHS430, Very Low-Dose Oral Interferon Alpha (VELDONA) and Synthetic RNA (SRNA). Its Ainos Flora device is intended to perform a non-invasive test for female vaginal health and certain common sexually transmitted diseases (STDs). Ainos Pen device is a cloud-connected, multi-purpose, portable breath analyzer that is intended to monitor health conditions. The CHS430 device is intended to provide non-invasive testing for ventilator-associated pneumonia.
ο»Ώ

NDAQ:AIMD - Post by User

<< Previous
Bullboard Posts
Next >>
Post by CashSeekeron Dec 02, 2024 4:48pm
22 Views
Post# 36341563

$AIMD πŸš€ Exciting Update! πŸš€

$AIMD πŸš€ Exciting Update! πŸš€Ainos has signed an MOU with Taiwan Tanabe Seiyaku Co., Ltd. to advance the production and marketing of Sjgren's syndrome drug, VELDONA, in Taiwan. This international partnership taps into Taiwan Tanabe's strong pharmaceutical expertise and market presence.

As part of Mitsubishi Tanabe Pharma Corporation in Japan, Taiwan Tanabe excels in key therapeutic areas, addressing the significant need for effective Sjgren's syndrome treatments. Ainos has conducted three Phase 3 studies showing significant benefits in increasing saliva secretion for Sjgren's syndrome patients. Despite its impact, there is still a big need for effective treatments. Together, they are committed to improving patient lives!
<< Previous
Bullboard Posts
Next >>